article · Virus Research
• First Cameroonian study to identify HCV core mutations associated with hepatocellular carcinoma (HCC) in treatment-naive patients. • Predominance of genotype 4 (41.97%) and subtype 4f (18.59%), associated with an increased risk of HCC. • Detection of oncogenic mutations (R70Q, T72E, K74R, G77A) and 278 amino acid substitutions in the core region. • Significant associations between mutations, gender (female predominance) and time course (p < 0.05). • Phylogenetic and epidemiological data essential for HCV surveillance and HCC prevention in Cameroon. In Cameroon, infection with the hepatitis C virus (HCV) is a major factor in hepatocellular carcinoma (HCC). Cirrhotic patients, even when treated with direct-acting antivirals (DAAs), may still be at risk of developing HCC. The aim of this study was to identify mutations associated with the development of HCC in treatment-naive HCV-infected patients, in order to understand the molecular mechanisms involved in this local context. From 2013 to 2023. 1065 HCV-infected Cameroonian patients provided blood samples. Plasma, isolated and stored at -80°C, was used to amplify the Core gene using specific primers. Nucleotide sequences obtained by Sanger sequencing were analyzed with IQ-Tree for phylogenetic studies. Sequences were edited and aligned using Mega and MAFFT, and mutation searches were performed manually using AliView software. Three genotypes (1, 2, 4) were identified, with genotype 4 predominating. Several mutations known to play an oncogenic role were detected: K10R (0.66%), R70Q (10.52%), T72E (80.56%), K74R (82.82%), G77A (70.53%) and C/L91M (0.09%). A hundred other mutations potentially linked to response to AADs were also observed. The analysis revealed mutations significantly related to sex and year, such as (K115R, N106S, T48A) with p-values of (0.0023; 0.0006), (0.0012; 0.0004) and (0.0045; 0.0058) respectively. This study provides the first comprehensive mapping of HCV core mutations in Cameroon, identifying variants potentially linked to HCC. Although limited by the lack of clinical follow-up, it underscores the urgency of monitoring these mutations in national HCV elimination programs, in line with the WHO's goals for 2030.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.virusres.2025.199659
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
